Nutrition Research and Practice

The Korean Nutrition Society (한국영양학회)
권호 표지

Apoptotic effect of $IP_6$ was not enhanced by co-treatment with myo-inositol in prostate carcinoma PC3 cells

  • Kim, Hyun-Jung (Department of Food and Nutrition, Seoul National University) ;
  • Jang, Yu-Mi (Department of Food and Nutrition, Seoul National University) ;
  • Kim, Harriet (Department of Food and Nutrition, Seoul National University) ;
  • Kwon, Young-Hye (Research Institute of Human Ecology, Seoul National University)
  • Published : 2007.09.20
Download PDF
⟨ Previous Next ⟩

Abstract

Inositol hexaphosphate ($IP_6$) is a major constituent of most cereals, legumes, nuts, oil seeds and soybean. Previous studies reported the anticancer effect of $IP_6$ and suggested that co-treatment of $IP_6$ with inositol may enhance anticancer effect of $IP_6$. Although the anticancer effect of $IP_6$ has been intensively studied, the combinational effect of $IP_6$ and inositol and involved mechanisms are not well understood so far. In the present study, we investigated the effect of $IP_6$ and myo-inositol (MI) on cell cycle regulation and apoptosis using PC3 prostate cancer cell lines. When cell, were co-treated with $IP_6$ and MI, the extent of cell growth inhibition was significantly increased than that by $IP_6$ alone. To identify the effect of $IP_6$ and MI on apoptosis, the activity of caspase-3 was measured. The caspase-3 activity was significantly increased when cells were treated with either $IP_6$ alone or both $IP_6$ and MI, with no significant enhancement by co-treatment. To investigate the effect of $IP_6$ and MI of cell cycle arrest, we measured p21 mRNA expression in PC3 cells and observed significant increase in p21 mRNA by $IP_6$. But synergistic regulation by co-treatment with $IP_6$ and MI was not observed. In addition, there was no significant effect by co-treatment compared to $IP_6$ treatment on the regulation of cell cycle progression although $IP_6$ significantly changed cell cycle distribution in the presence of MI or not. Therefore, these findings support that $IP_6$ has anticancer function by induction of apoptosis and regulation of cell cycle. However, synergistic effect by MI on cell cycle regulation and apoptosis was not observed in PC3 prostate cancer cells.

Keywords

References

  1. Agarwal C, Dhanalakshmi S, Singh R & Agarwal R (2004). Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia 6:646-659 https://doi.org/10.1593/neo.04232
  2. Diallo JS, Peant B, Lessard L, Delvoye N, Le Page C, Mes-Masson AM & Saad F (2006). An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. Prostate 66:1245-1256 https://doi.org/10.1002/pros.20455
  3. Estensen R & Wattenberg L (1993). Studies of chemopreventive effects of myo-inositol on benzo[a]pyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 14: 1975-1977 https://doi.org/10.1093/carcin/14.9.1975
  4. Ferry S, Matsuda M, Yoshida H & Hirata M (2002). Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFkB-mediated cell survival pathway. Carcinogenesis 23:2031-2041 https://doi.org/10.1093/carcin/23.12.2031
  5. Grases F, Simonet B, Vucenik I, Perello J, RM P & Shamsuddin A (2002). Effects of exogenous inositol hexakisphosphate (InsP(6)) on the levels of InsP(6) and of inositol trisphosphate (InsP(3)) in malignant cells, tissues and biological fluids. Life Sci 71: 1535-1546 https://doi.org/10.1016/S0024-3205(02)01927-6
  6. Isaacs W, Carter B & Ewing C (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720
  7. Morgan DO (1995). Principles of CDK regulation. Nature 974: 131-134
  8. Razzini G, Berrie C, Vignati S, Broggini M, Mascetta G, Brancaccio A & Falasca M (2000). Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J 14:1179-1187 https://doi.org/10.1096/fasebj.14.9.1179
  9. Reddy N, Sathe S & Salunkhe D (1982). Phytates in legumes and cereals. Adv Food Res 28:1-92
  10. Sakamoto K, Venkatraman G & Shamsuddin A (1993). Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). Carcinogenesis 14:1815-1819 https://doi.org/10.1093/carcin/14.9.1815
  11. Sasakawa N, Sharif M & Hanley M (1995). Metabolism and biological activities of inositol pentakisphosphate and inositol hexakisphosphate. Biochem Pharmacol 50:137-146 https://doi.org/10.1016/0006-2952(95)00059-9
  12. Shamsuddin A (1999). Metabolism and cellular functions of IP6: a review. Anticancer Res 19:3733-3736
  13. Shamsuddin A, Ullah A & Chakravarthy A (1989). Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice. Carcinogenesis 10:1461-1463 https://doi.org/10.1093/carcin/10.8.1461
  14. Shamsuddin A, Vucenik I & Cole K (1997). IP6: A novel anti-cancer agent. Life Sci 61:343-354 https://doi.org/10.1016/S0024-3205(97)00092-1
  15. Shamsuddin A, Yang G & Vucenik I (1996). Novel anti-cancer functions of IP6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. Anticancer Res 16:3287-3292
  16. Singh RP, Agarwal C & Agarwal R (2003). Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRB-related protein-E2F complexes. Carcinogenesis 24:555-563 https://doi.org/10.1093/carcin/24.3.555
  17. Singh RP, Sharma G, Mallikarjuna G, Dhanalakshm S, Agarwal C & Agarwal R (2004). In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res 10:244-250 https://doi.org/10.1158/1078-0432.CCR-1080-3
  18. Venkateswaran V, Klotz LH & Fleshner NE (2002). Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 62:2540-2545
  19. Vucenik I, Ramakrishna G, Tantivejkul K, Anderson L & Ramljak D (2005). Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation. Breast Cancer Res Treat 91:35-45 https://doi.org/10.1007/s10549-004-6456-5
  20. Vucenik I & Shamsuddin A (2003). Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr 133:3778S-3784S https://doi.org/10.1093/jn/133.11.3778S
  21. Vucenik I, Tantivejkul K, Zhang Z, Cole K, Saied I & Shamsuddin A (1998a). IP6 in treatment of liver cancer. I. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 18:4083-4090
  22. Vucenik I, Yang G & Shamsuddin A (1995). Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. Carcinogenesis 16:1055-1058 https://doi.org/10.1093/carcin/16.5.1055
  23. Vucenik I, Zhang Z & Shamsuddin A (1998b). IP6 in treatment of liver cancer. II. Intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice. Anticancer Res 18:4091-4096
  24. Zi X, Singh R & Agarwal R (2000). Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 21:2225-2235 https://doi.org/10.1093/carcin/21.12.2225